On Friday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $1.27 which represents a decrease of $-0.03 or -2.31% from the prior close of $1.3. The stock opened at $1.3 and ...

Shares of Lexicon Pharmaceuticals tanked nearly 33.6% as of 11:30 am ET after the drug company’s sotagliflozin drug candidate received a negative vote by a US Food and Drug Administration (FDA) panel, ...

In recent trading, Lexicon Pharmaceuticals Inc (LXRX) stock price has shown some volatility, fluctuating -33.33% over the last five trades and -22.62% over the past 30 trades. This represents a ...

While an FDA advisory committee saw signals of efficacy for Lexicon Pharmaceuticals’ sotagliflozin, the panel of external ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' ...

Lexicon Pharmaceuticals shares have been halted all day as a Food and Drug Administration advisory committee was scheduled to vote on Zynquista as an adjunct to insulin therapy for glycemic control in ...

A simultaneous webcast will be available in the “Events” section of the Lexicon website at and a recording of the webcast will be available for two weeks following the original on-demand date. About ...

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases.

H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on LXRX stock, giving a Buy rating on October 17. Joseph ...

The deal is a boost to Lexicon, because the company was unlikely to try to sell Inpefa outside of the U.S. on its own, according to Jefferies’ Tsai. Meanwhile, the drug fits into plans by ...